Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13D/A for LB Pharmaceuticals Inc Common Stock, $0.0001 par value per share (LBRX).
- Disclosed ownership: 12%.
- Date of event: 06 Feb 2025.
Deep Track Capital, LP - 06 Feb 2025 SCHEDULE 13D/A Report for LB Pharmaceuticals Inc Common Stock, $0.0001 par value per share (LBRX)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- LBRX
- Shares outstanding
- 28,656,444 shares
- Disclosed Ownership
- 3,352,804 shares
- Ownership
- 12%
- Form type
- SCHEDULE 13D/A
- Filing time
- 10 Feb 2026, 16:30:44 UTC
- Date of event
- 06 Feb 2025
- Next filing
- 19 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 12% ownership in LB Pharmaceuticals Inc Common Stock, $0.0001 par value per share (LBRX) on 06 Feb 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Feb 2026, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | 9.4% | 2,686,138 | 0 | 2,686,138 | /s/ David Kroin | David Kroin, Director | |
| Deep Track Special Opportunities Fund, LP | 2.3% | 666,666 | 0 | 666,666 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Manager | |
| Deep Track Capital, LP | 12% | 3,352,804 | 0 | 3,352,804 | /s/ David Kroin | David Kroin, Managing Member of the General Partner | 0001856083 |
| David Kroin | 12% | 3,352,804 | 0 | 3,352,804 | /s/ David Kroin | David Kroin |